Effects of Isoproterenol (beta-adrenergic agonist) on in vitro differentiation of human mesenchymal stem cells into osteoblasts

The importance of β-adrenergic signals in bone formation and resorption has been well investigated. However, little is known about the role of β -adrenergic signals in osteoblastic differentiation of mesenchymal stem cells (MSCs), which is critically important in bone physiology and pharmacology. In this study, RUNX2 and Osteocalcin gene expression were quantified in MSCs differentiated by osteoblastic differentiation medium (ODM) and Isoproterenol (ISO). In this experimental study, human mesenchymal stem cells were treated by osteoblastic differentiation medium and ISO. RNA extraction was carried out from both osteoblastic differentiation medium at 4 and 21 days of differentiation and from undifferentiated MSCs. RUNX2 and osteocalcin gene expression were quantified by quantitative Real Time-PCR. Isoproterenol decreased the expression of RUNX2 and osteocalcin genes at 4 and 21 days of osteoblastic differentiation. Statistically significant difference was found at 21 days of differentiation (P<0.05). Isoproterenol negatively affects MSC osteogenesis. These findings suggest that human mesenchymal stem cell is also a target for β-adrenergic and may provide valuable treatment option in bone diseases. References 1- Serre CM, Farlay D, Delmas PD, Chenu C. Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers.